phase ii cf cystinosi start initi overweight w/ target
initi coverag eloxx overweight rate price target eloxx
develop therapi treat genet diseas caus nonsens mutat
cystic fibrosi cf cystinosi eloxx complet singl ascend phase ia
studi lead candid conduct multipl ascend phase ib studi
look preclin data european cystic fibrosi confer june
inform mechan eloxx plan initi phase ii studi cf
cystinosi eloxx revers merg decemb
compani recent issu million share bring pro forma cash
million fund oper
novel dual mechan protein restor novel eukaryot
ribosom select glycosid ersg compound select bind human
ribosom enabl read stop codon translat full length function
protein importantli dual mechan wherebi impact nonsense-
mediat mrna decay nmd prevent degrad result mrna
increas protein output eloxx novel ersg potenti treat sever genet
diseas caus nonsens mutat eloxx intend select next candid
target diseas year
phase ii cf start estim cf patient cftr
nonsens mutat treat vertex pharmaceut ow
current therapi repres signific unmet need littl competit
anticip addit preclin data european cystic fibrosi
confer june compani plan begin phase ii studi nonsens
mutat cf proof-of-concept data next year present anticip
approv forecast global cf sale billion
phase ii cystinosi start eloxx also develop treat cystinosi
ultra-rar lysosom storag diseas mediat nonsens mutat eloxx plan
begin phase ii studi cystinosi also proof-of-concept
data next year anticip approv cystinosi forecast global
sale million
may fail clinic fail gain regulatori approv eloxx may unabl file
ind compani like requir futur fund
eloxx develop ersg treat genet diseas caus nonsens mutat
eloxx merg publicly-trad sevion
therapeut decemb
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
make sens nonsens mutat advanc
phase ii cystic fibrosi cystinosi studi
eloxx develop small molecul drug treat genet diseas caus
nonsens mutat restor product function protein nonsens
mutat also known prematur termin codon caus earli stop
translat result truncat non-funct protein accord human gene
mutat databas mutat result caus diseas
cystic fibrosi cf cystinosi duchenn muscular dystrophi dmd rett
syndrom mucopolysacchardosi major condit lack
lead candid eukaryot ribosom select glycosid ersg work
select bind human ribosom enabl read stop codon
translat full length function protein also impact nonsens mediat
mrna decay nmd prevent degrad result mrna increas
protein output dual mechan eloxx novel ersg potenti amen
treat sever genet diseas caus nonsens mutat
eloxx complet singl ascend phase ia studi healthi
volunt show accept safeti profil sae death compani
conduct phase ib multipl dose studi healthi volunt
compani present addit preclin data european cystic fibrosi
confer june initi phase ii studi nonsens mutat cf
estim cf patient nonsens mutat treat
vertex pharmaceut overweight current therapi repres
signific unmet need littl competit see opportun eloxx
leader nmcf forecast global cf sale billion
eloxx also plan begin phase ii studi orphan indic cystinosi
cystinosi ultra-rar autosom recess lysosom storag diseas caus
nonsens mutat result accumul amino acid cystin cystagon
procysbi market treat cystinosi expens complianc issu
adult procysbi averag annual price expect fda approv
cystinosi forecast global sale million
eloxx screen ersg could develop treat genet diseas
caus nonsens mutat receiv orphan drug design
fda treat cystinosi rett syndrom ema
expect eloxx announc next compound target diseas sometim year
proce million bring pro forma cash million look eloxx
creat valu advanc clinic cf cystinosi well pursu
genet diseas underli nonsens mutat
present preclin data european cystic fibrosi confer june
complet phase ib mad studi healthi volunt
announc next target diseas caus nonsens mutat year
initi phase ii studi cystic fibrosi
initi phase ii studi cystinosi
publicly-trad sevion therapeut
page
initi coverag eloxx overweight rate price
target base project enterpris valu million plu project cash
valu cf million appli standard multipl
sale million discount back valu elx-
cf europ million appli multipl sale
million discount back view discount rate
appropri phase ib drug character mechan action could
adjust phase ii data next year
valu cystinosi million appli multipl
sale million discount back valu
cystinosi europ million appli multipl sale
million discount back view discount rate
appropri could adjust phase ii data
add million valu preclin rett syndrom program
receiv orphan drug design fda
eloxx end cash million compani subsequ issu
million share rais gross proce million estim eloxx
hold pro forma cash million fund oper
thu add project cash million divid project market cap
million million share arriv price target
pleas see exhibit
page
eloxx trade current market cap million pro forma cash million
equat enterpris valu million compani cf/orphan diseas comp
group trade averag market cap billion ev billion
exclud commerci play vertex sarepta overweight comp group
trade averag market cap million ev million see
therapeut eloxx closest comp trade current market cap billion
ev billion pleas see exhibit see opportun eloxx
close valuat gap report phase ii data cf cystinosi next year
progress toward phase trial advanc addit compound clinic
sec document factset corpor compani report piper jaffray estim
pro forma cash share count includ recent equiti offer ltd includ full convert note princip
pro forma cash share count includ recent equiti offer
page
excl excl nmd
nonsens mutat caus prematur termin codon messeng rna
mrna convert sens codon stop codon uag uga
way act stop signal recruit releas factor prematur halt
translat mrna protein result truncat protein product
either inactiv non-funct accord human gene mutat databas
mutat single-point mutat caus prematur stop codon
krawczak et al human mutat known
uniqu mutat human gene equat approxim mutat
result
accumul truncat protein toxic mammalian cell adopt
housekeep mechan monitor elimin aberr mrna carri ptc
known nonsens mediat mrna decay nmd nmd trigger presenc
involv complex set interact protein includ upf factor
regul effector upf factor translat termin
factor nmd initi mrna target degrad exonucleas
one approach overcom nonsens mutat translat read-through
approach small molecul bind ribosom order skip facilit
insert cognat trna carri amino acid allow translat full-
length protein howev suppress alon often suffici produc
enough full-length protein restor biolog function due degrad result
mrna nmd number mrna reduc amount protein
produc even via suppress limit use nmd
suppressor affect assembl nmd factor therebi increas
number mrna complement suppress product protein
therapeut level pleas see exhibit
nmd
page
proof suppress nmd lead increas stabil ptc-contain mrna
come experi epitheli cell nonsens mutat caus
cystic fibrosi treat cycloheximid chx known nmd inhibitor chx
treat cell show increas number mrna compar untreat cell
furthermor inhibit nmd occur specif cell contain
nonsens mutations/ptc cell cf mutat exhibit
effect nmd inhibit mrna level
adopt et al
among propos mechan inhibit compon nmd
valid approach inhibit nmd factor antisens
oligonucleotid result select stabil contain mrna
lind et al work shown attenu nmd increas
abund contain mrna enhanc addit
aminoglycosid antibiot bind bacteri ribosom prevent protein
translat bacteria mammalian cell aminoglycosid bind ribosom
induc conform chang reduc codon-anticodon recognit
weak selectivity/fidel ribosom allow insert cognat trna
carri amino acid region instead releas factor termin
translat thu aminoglycosid act suppressor
howev limit read-through effici toxic limit factor
advanc aminoglycosid read-through therapi select
aminoglycosid bacteri ribosom high dose requir affect eukaryot
ribosom caus kidney tox impact gut bacteri flora addit perman
hear impair report aminoglycosid gentamicin
shown promis suppressor exhibit highest read-through
aminoglycosid despit potenc toxic mammalian cell
ideal therapeut choic
page
eukaryot ribosom select glycosid ersg molecul
screen select human ribosom decreas affin bacteri
ribosom unlik first gener suppressor low affin
bacteri ribosom improv safeti profil drug specif decreas
mitochondri tox caus aminoglycosid addit
modif prevent entri cochlear cell channel
potenti reduc ototox observ aminoglycosid treatment
addit select bind mammalian ribosom potenti
destabil nmd assembl contain mrna one factor play role
initi nmd instabl ribosom movement along mrna
translat brought presenc role stabil
kinet ribosom movement along mrna inhibit could
suppress nucleat nmd slow rate mrna decay result
potenti increas abund ptc-contain mrna two
complementari therapeut properti differenti small molecul
eloxx complet phase ia singl ascend dose studi seven dose cohort
rang iv sc healthi volunt israel belgium
data await public safe acut chronic
chang serum creatinin evid aberr translat read-through
housekeep gene ototox observ sae death report
result dsmb clear eloxx commenc phase ib multipl ascend
dose studi on-going belgium total healthi volunt
random five cohort receiv nine dose placebo
compani clear first two dose cohort screen third
expect final phase ib mad data import note complet
studi imped initi plan phase ii trial cf cystinosi
importantli eloxx screen pool novel esrg compani
present work select new molecul develop genet diseas
caus nonsens mutat duchenn muscular dystrophi dmd
mucopolysacchardosi mp rett syndrom receiv orphan drug
design mp fda ema rett syndrom fda
expect compani announc next compound target diseas sometim
page
cf autosom recess monogen inherit diseas affect patient
world-wide higher preval amongst caucasian accord cystic
fibrosi foundat patient registri cf popul estim
patient cf caus loss function mutat cystic fibrosi
cftr mutat class type effect approxim cftr
mutat caus cf vast major exceedingli rare import
rememb overlap mutat patient homozyg
copi heterozyg copi given mutat accord cf foundat
patient registri data common mutat account
cf patient includ homozyg heterozyg
split anoth way approxim cf patient make function cftr
reach cell surfac ion channel open patient treatabl
vertex potenti kalydeco ivacaftor bind cftr cell surfac
open ion channel potenti chlorid cl- passag anoth cf
patient produc misfold cftr degrad proteasom reach
cell surfac mutat address vertex orkambi lumacaftor
ivacaftor fold cftr properli transport epithelia open cftr cell
surfac recent vertex gain approv symdeko combin
cftr corrector tezacaftor kalydeco
remain patient approxim carri nonsens mutat
cftr gene classifi class nonsens mutat current
approv therapi class mutat produc function cftr protein
among class mutat nonsens mutat creat lead truncated/non-
function cftr common mutat includ
current approv therapi address class mutat repres huge
unmet need pleas see exhibit
page
measur
key factor whether therapeut effect minimum level
defect cftr protein function restor achiev clinic effect measur
threshold differ among individu estim
normal cftr activ requir clinic benefit eitan et al row et al
new preclin assay assess activ cftr modul therapi
measur forc induc swell organoid patient biopsy-deriv
cell cultur organoid swell follow administr therapeut agent specif
cell surfac transport cftr drug efficaci produc
function protein organoid swell correl
organoid valid measur clinic respons
incub organoid cultur hour result dose depend
vitro swell organoid cultur homozyg mutat
demonstr therapeut activ drug synergist effect
observ kalydeco ad incub organoid cultur
carri mutat pleas see exhibit
vitro activ organoid cultur cftr mutat
vitro activ organoid cultur cftr mutat /- kalydeco
page
vitro studi heterozyg human bronchial
epitheli cell show induct wild type ctfr level hour
mutant mice twice-weekli treatment result
increas cftr activ versu control preclin data present
european cystic fibrosi confer june belgrad
follow cta ind file eloxx target phase ii studi start cf
phase ii trial design yet disclos expect eloxx
follow regulatori preced set vertex kalydeco mean expect eloxx
conduct studi primari efficaci endpoint nasal potenti
differenti sweat chlorid key secondari endpoint importantli
patient may organoid elect donat studi
anticip phase ii data inform go forward dose pivot studi
present anticip eloxx commenc phase trial
primari endpoint earli
base timelin anticip could gain fda approv
europ anticip similar price vertex kalydeco gross
net base address patient popul project sale
million million grow million project
european sale million million grow million
total equat global cf sale million
million grow billion pleas see exhibit
cf foundat compani report piper jaffray estim
page
unit fibrosi nonsens treat sale fibrosi nonsens treat sale cf sale cystinosi
eloxx also develop cystinosi ultra-rar autosom recess
lysosom storag diseas cystinosi estim affect live
birth cystinosi multisystem genet disord caus mutat
gene encod lysosom membran transport protein cystinosin cystinosin
respons remov amino acid cystin lysosom mutat
gene result defect cystinosin protein subsequ accumul
lysosom differ organ includ kidney eye liver brain store cystin
poorli solubl form crystal lead tissu organ damag
three major form cystinosi nephropat cystinosi intermedi cystinosi
ocular cystinosi nephropat cystinosi common sever form
account case patient ultim requir kidney transplant
fda approv cystagon cysteamin bitartr follow extend
releas formul procysbi treatment cystinosi adult
children procysbi receiv market author ema approv
procysbi base open label trial compar extend releas formul
immediate-releas cystagon util white blood cell cystin concentr
measur effect trial demonstr procysbi non-inferior
mean cystin level nmol/mg protein vs nmol/mg protein
therapi work convert cystin cystein cysteine-cysteamin mix
disulfid exit lysosom via mechan independ defect
cystinosin protein approv two cystin deplet therapi along
improv kidney transplant lifespan patient cystinosi
extend follow administr drug cystin content
white blood cell decreas rapidli requir chronic dose maintain low
level result cystine-deplet agent taken life patient
cystin deplet agent revers kidney dysfunct shown
slow progress kidney damag howev complic cystinosi
abrog cystin deplet agent includ incid primari hypogonad
infertil addit corneal crystal address system
administr requir topic eye drop foul tast smell agent
led complianc issu major issu interrupt lead rapid
re-accumul cystin lead irrevers tissu damag procysbi
one expens approv therapi averag annual price
adult patient remain unmet need therapi
address underli diseas extend life patient
page
studi
vitro studi shown suppress nmd result higher level
accumul patient fibroblast without caus cellular toxic
mous model cystinosi similar result observ administ
mg/kg sc twice week week reduc cystin accumul
without renal toxic valid approach pleas see exhibit
vitro efficaci cystinosi
mous model cystinosi similar result observ administ
mg/kg sc twice week week reduc cystin accumul
without renal toxic valid approach pleas see exhibit
efficaci cystinosi mice model
page
eloxx intend initi phase ii studi cystinosi data next
year present anticip compani conduct phase trial could gain
fda approv cystinosi europ anticip
similar respons price cf estim net
net europ upon launch repres signific discount horizon procysbi
project sale million million grow million
project european sale million million grow
million total equat global cf sale million
million grow million pleas see exhibit
compani report piper jaffray estim
page
unit nonsens patient nonsens treat cystinosi sale nonsens patient nonsens treat cystinosi sale cystinosi sale nmcf studi
cover develop translarna ataluren treat
genet diseas caus nonsens mutat translarna grant condit
approv treat nonsens mutat dmd nmdmd ema august
howev fda histor challeng activ molecul
approv translarna nmdmd fact fda issu refuse-to-fil rtf letter
two separ occas second follow two clinic
studi appeal rtf letter culmin
adcom meet held septemb agenc conclud data studi
prove translarna clinic benefit therefor approv drug
translarna also fail demonstr benefit two pivot phase nonsens mutat
compani subsequ discontinu
develop indic thu date translarna receiv fda approv
indic
translarna oral molecul believ promot read-through
propos mechan action involv interact ribosom decreas
sensit codon stop signal allow insert near-
cognat trna site nonsens codon translarna suspect interact
ribosom howev believ impact nmd mrna stabil du et al
pna despit extens character physic
interact translarna ribosom yet elucid
demonstr translarna exposur cf vivo model express
mutant human cftr demonstr cftr express surfac intestin
epitheli cell trans-epitheli chlorid conduct translarna appear activ
highest subcutan dose lower dose
use oral translarna formul dissolv solut higher dose
translat trans-epitheli chlorid conduct averag chlorid
current measur wild-typ mice activ higher dose consist
subcutan data du et al pna
interestingli vivo analys demonstr translarna-medi cftr
epitheli express chlorid conduct lower subcutan oral dose du
et al attribut find bioavail translarna plasma measur
demonstr decreas drug concentr hour inject vivo
studi suggest plasma concentr ug/ml translarna optim
nonsens suppress perhap explain lack activ dose du et al pna
howev note compani elect pursu lower
two translarna dose regimen cf clinic trial suggest lack dose-depend
correl vivo data clinic activ nmdmd vitro data suggest
invert u-shap dose respons support vivo dystrophin
express lack dose-depend activ one factor signal concern
clinic explor anoth red flag failur public replic
translarna read-through capac cf model
organoid becom preval tool cf research evalu function
marker activ novel therapi organoid structur develop
stem cell mimic human lung structur function system becom
favor abil rapidli gener reliabl function data novel therapi
across cftr mutat forskolin induc organoid swell
indic cftr-mediat chlorid channel conduct mutant cftr model
swell compromis thu molecular restor swell offer
page
surrog marker therapeut benefit zomer-van ommen et al analyz activ
translarna geneticin antibiot well-character read-through
capac four differ nonsens mutat
human cf organoid exposur result limit swell
significantli improv combin vertex orkambi howev swell
activ observ translarna singl agent combin orkambi
zomer-van ommen et al journal cystic fibrosi
data support prior studi confirm read-through activ translarna
vitro mcelroy et al use cell-bas firefli luciferas fluc report assay
express in-fram exposur translarna demonstr significantli
lower fluoresc compar public also show translarna
demonstr compar luminesc wild-typ fluc construct indic non-
select nonsens mutat variou sequenc ident
nucleotid follow posit influenc protein restor
low level activ report translarna essenti differ
control media lack translarna activ variou vitro report assay
replic sever public auld et al pna
ad weight contradictori preclin literatur conduct
two phase trial translarna nmcf fail meet primari secondari
endpoint statist signific first second result
first phase trial nmcf publish lancet
popul includ patient random translarna placebo oral
translarna administ three time daili
dose respect primari endpoint rel chang percent predict
met statist signific translarna show declin
versu placebo secondari pulmonari exacerb rate endpoint
lower translarna treat patient versu placebo statist
signific safeti toler favor death relat sae
perhap anoth sign drug lower activ purport preclin
unblind conduct post-hoc analysi evalu
primari secondari endpoint patient translarna placebo
receiv chronic inhal tobramycin prior enrol rational base
vitro analys roy et al exhibit activ translarna reduc
dose-depend fashion upon addit tobramycin tobramycin known bind
ribosom site observ translarna reduc activ antibiot
presenc may suggest competit site roy et al pna
find support post-hoc analys first
statist signific mean declin week vs declin
placebo arm mean rel chang end studi
pulmonari exacerb rate lower translarna adjust
howev like inher bia creat post-hoc analys
unblind data led second phase nmcf trial failur ident endpoint
first phase studi invalid tobramycin theori result particularli
disappoint sinc popul enrich magnifi lack translat
vivo find clinic propag disbelief translarna
mechan sinc discontinu evalu translarna
primari endpoint
page
reoccur peculiar theme translarna consist clinic failur across
nonsens mutat diseas even enrich popul beg question
whether drug truli activ detail numer
independ public fail replic translarna read-through capac across
sever report assay compar activ classic read-through molecul
and/or gentamicin fact studi suggest translarna activ
luciferase-report assay may result molecul bind stabil
enzym cell-report system trace constant amount luciferas may
detect due leaki translarna target stabil enzym could
mean luminesc signal mistakenli attribut translarna-medi read-through
mutat cast doubt mechanist activ
reconcil discrep preclin activ translarna fail clinic
outcom nmcf nmdmd challeng fail clinic outcom may
attribut lack dose-respons inadequ character optim
therapeut dose anoth explan could relat observ
translarna affect nmd complex formul mrna stabil
translarna may reduc rate nmd-mediat degrad fail
produc adequ level function protein clinic disappoint nmdmd
nmcf studi bear signific claim mechan
translarna would applic genet diseas nonsens mutat
failur one suggest failur accord compani definit mechan
trial enrich also appear impact observ therapeut benefit
overal wager much money legal interact
fda molecul plainli activ
intellectu properti licens agreement technion
eloxx enter licens agreement technion research
develop foundat trdf israel institut technolog world-wide
exclus right develop commerci technolog relat aminoglycosid
treat human genet diseas caus prematur stop codon eloxx owe trdf pre-
specif mileston royalti product deriv aminoglycosid technolog
mileston payment trdf licens product includ payment
upon first dose patient phase ii clinic studi upon first dose
patient pivot studi upon first file nda low-to-mid singl digit
eloxx licens patent applic subsequ patent cooper
treati pct lead compound provid protect
europ japan canada israel composit matter method use use
combin therapi eloxx estim patent protect
eloxx also file patent applic treat genet diseas includ cf
cystinosi dmd ataxia-telengiectasia hurler syndrom hemophilia usher
syndrom tay-sach rett syndrom includ combin therapi exist
treatment cftr modul cf
eloxx file four pct applic gener relat new composit
matter method treat genet diseas recent march
compani file patent applic india relat large-scal manufactur elx-
new compound plan file similar patent issu
patent would expir
page
chairman ceo
safeti
robert ward becam chairman board ceo eloxx pharmaceut decemb
mr ward previous presid ceo radiu health respons launch
new drug tymlo inject treatment osteoporosi mr ward held
seri senior role np pharmaceut schering-plough merck pharmacia
bristol-my squibb genentech mr ward earn biolog
physiolog psycholog uc santa barbara manag new jersey
institut technolog immunolog john hopkin univers school
dr pedro huerta serv chief medic offic eloxx dr huerta previous
clinic lead head precis medicin diseas led clinic team
regist fabrazym eu japan dr huerta earn medic degre
program health scienc technolog harvard medic school mit
ph harvard univers cell development biolog master manag
sloan school manag mit
dr neal sharp senior director preclin safeti previous dr sharp serv
act head program director al diseas led multipl project schering-
plough prior acquisit merck dr sharp hold ph neurosci rutger
gregori weaver chief offic eloxx mr weaver serv cfo
mr weaver earn mba boston colleg certifi
result eloxx merger publicly-trad decemb
compani limit histor financi result
eloxx report histor revenu forecast revenu forese futur
eloxx invest million project invest increas
million million compani advanc phase ii studi
cf cystinosi later year
eloxx spent million sg budget compani spend million
sg grow million
compani report net loss million per share project net loss
million million
eloxx end cash million compani subsequ issu
million share rais gross proce million estim eloxx
hold pro forma cash million fund oper
page
risk associ eloxx common drug discovery/develop
compani includ clinic regulatori commerci ersg novel class
drug therapeut face multipl regulatori setback may
fail clinic fail gain regulatori approv eloxx could face competit
biotech compani gene therapi and/or gene edit approach
increas awar drug price eloxx may unabl charg premium
price therapi may reach sale project
compani may unabl file ind advanc new therapeut candid
clinic eloxx may unabl sign new collabor eloxx like requir addit
capit eloxx could face futur unforeseen litig may forc defend
rate price target risk
rate apr close overweight price target base
non-gaap dilut ep disc thru risk includ cf drug may fail
clinic gain approv may meet expect
rate apr close overweight price target base
project ev net cash risk includ eteplirsen may approv
sarepta may launch eteplirsen turn profit requir addit fund
capit market
page
research develop
gener administr
incom expens
thousand except per share
net income/ loss attribut common stockhold
compani report piper jaffray estim
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
